Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

Peeing shouldn't be painful-yet all too often it is. If you've found yourself wondering "Why does it burn when I pee?", ...

It is commonly discussed in the context of vaginal infections, but what many do not realize is that men can also suffer from ...

The symptoms of vulvovaginal atrophy, such as vaginal dryness, irritation, itching, dysuria and dyspareunia ... Local estrogen therapy is the treatment of choice for women with vulvovaginal ...

Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment ...

Porizkova, 59, says women "don’t need a steady partner, just a desire to explore" their sexuality as they age.

Ferring Pharmaceuticals announced today three abstracts featuring ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025 American Society of Clinical Oncologists Genitourinary ...

In addition, adulterants in drugs can cause rashes at injection sites ... He reported no diarrhea, dysuria, abdominal pain, nausea, vomiting, or vision changes. Although his use of emtricitabine ...

The patient reported no chest pain, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, abdominal pain, diarrhea, vomiting, dysuria ... and anxiety. Medications included aspirin, ticagrelor ...

The risk factors for treatment non-adherence include dosing ... exacerbation of psychosis and dysuria. The use of concomitant anticholinergics decreased from 15.0% to 8.3%. Conclusions The results ...